Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Nov 13, 2024

(R) Cantargia presents Nomination Committee ahead of 2025 AGM

Nov 11, 2024

Cantargia results showing efficacy of CAN10 in models of myocarditis published in Circulation: Heart Failure

Nov 6, 2024

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Nov 6, 2024

(R) Cantargia resolves on a rights issue of approximately SEK 170 million

Nov 5, 2024

Cantargia presents promising preclinical results on nadunolimab with antibody-drug conjugates at major immuno-oncology conference

Nov 1, 2024

Invitation to presentation of Cantargia’s interim report January – September 2024

Oct 28, 2024

(R) Cantargia reports new results from clinical studies investigating nadunolimab in several forms of cancer; supporting ongoing strategies

Oct 11, 2024

(R) Cantargia reports new positive results on biomarkers and safety in CAN10 phase 1 clinical study

Oct 10, 2024

Cantargia’s strong Phase 2 clinical data in pancreatic cancer with nadunolimab published in Clinical Cancer Research

Sep 30, 2024

(R) Cantargia reports start of multiple dosing part in CAN10 phase 1 clinical trial

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye